SCHEMBL5366371

SCHEMBL5366371

O=C1Nc2ccc(CCCl)cc2C1=Cc1cc(Br)cc(Br)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 10/20 0.50
LRRK2 Q5S007 4/20 0.50
PSEN1 P49768 1/20 0.50
PSEN2 P49810 1/20 0.50
APH1B Q8WW43 1/20 0.50
NCSTN Q92542 1/20 0.50
APH1A Q96BI3 1/20 0.50
PSENEN Q9NZ42 1/20 0.50
MAP1LC3B Q9GZQ8 3/20 0.49
PLK4 O00444 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PLK1 P53350 2/20 0.47
EGFR P00533 1/20 0.47
NTRK1 P04629 1/20 0.47
ARAF P10398 1/20 0.47
PIM1 P11309 1/20 0.47
BRAF P15056 1/20 0.47
CSNK2A1 P68400 1/20 0.47
PIM3 Q86V86 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363513 0.90 LRRK2 (0.55) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL5367287 0.88 LRRK2 (0.57) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL5361740 0.87 PLK4 (0.54) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL5377096 0.86 PLK4 (0.55) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL5358971 0.83 MAP1LC3B (0.70) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL5361064 0.81 RAF1 (0.46) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL7137032 0.81 RAF1 (0.72) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL7137229 0.80 MAP3K7 (0.50) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL5370082 0.79 LRRK2 (0.70) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL5367313 0.79 LRRK2 (0.56) RAF1LRRK2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
US-6506763-B2 Useful in prevention and treatment of protein kinase related disorders such as cancer SUGEN, INC. 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK RAF1 245/4885LRRK2 289/4885PSEN1 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.